- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Nucala® | SB-240563
mepolizumab is an approved drug (EMA & FDA (2015))
Compound class: Antibody
Comment: The Nucala® brand of mepolizumab is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells.
View more information in the IUPHAR Pharmacology Education Project: mepolizumab
|No information available.|
|Summary of Clinical Use|
|Mepolizumab is approved for the treatment of severe asthma in patients who are already taking other asthma medications [2,8].
In the United States and the European Union, mepolizumab can be used under orphan drug designation for the treatment of Churg-Strauss syndrome and hypereosinophilic syndrome.
Click here to link to ClinicalTrials.gov's full list of mepolizumab trials, including ongoing trials in additional eosinophilic conditions.
|Mechanism Of Action and Pharmacodynamic Effects|
|Mepolizumab antagonises IL-5 activity by effectively neutralising circulating IL-5. This leads to a reduction in eosinophil numbers in blood, tissue and sputum [3,7] and this effect underlies the drug's anti-inflammatory action [6,9].|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)